How to buy Intellipharmaceutics International (IPCI) stocks

Intellipharmaceutics International is a biotechnology business based in Canada. Intellipharmaceutics International shares (IPCI) are listed on the Toronto Stock Exchange (TSX) and all prices are listed in Canadian Dollars. Intellipharmaceutics International employs 11 staff and has a trailing 12-month revenue of around C$904,946.

Our top picks for where to buy Intellipharmaceutics International stock

Buy Intellipharmaceutics International stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Intellipharmaceutics International stock price (Toronto Stock Exchange (TSX): IPCI)

Use our graph to track the performance of IPCI stocks over time.

Intellipharmaceutics International stocks at a glance

• Key figures

Information last updated 2024-04-25.

52-week range	C$0.06 - C$0.10
50-day moving average more info button	C$0.08
200-day moving average more info button	C$0.09
Wall St. target price	C$2.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	C$-0.12

Is it a good time to buy Intellipharmaceutics International stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Intellipharmaceutics International financials

Revenue TTM	C$904,946
Gross profit TTM	C$65,728
Return on assets TTM	-107.39%
Return on equity TTM	0%
Profit margin	0%
Book value	C$-0.39
Market Capitalization more info button	C$2.6 million
EBITDA more info button	C$-2,407,400

TTM: trailing 12 months

Intellipharmaceutics International stock dividends

We're not expecting Intellipharmaceutics International to pay a dividend over the next 12 months.

Have Intellipharmaceutics International's stocks ever split?

Intellipharmaceutics International's stocks were split on a 1:10 basis on 13 September 2018 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intellipharmaceutics International stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for Intellipharmaceutics International stocks, which in turn could have impacted Intellipharmaceutics International's stock price.

Intellipharmaceutics International stock price volatility

Over the last 12 months, Intellipharmaceutics International's stocks have ranged in value from as little as C$0.06 up to C$0.1. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (TO average) beta is 1, while Intellipharmaceutics International's is 0.294. This would suggest that Intellipharmaceutics International's stocks are less volatile than average (for this exchange).

Intellipharmaceutics International overview

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Intellipharmaceutics International is owned by insiders?
Currently 1.757% of Intellipharmaceutics International stocks are held by insiders. How many people work for Intellipharmaceutics International?
Latest data suggests 11 work at Intellipharmaceutics International. When does the fiscal year end for Intellipharmaceutics International?
Intellipharmaceutics International's fiscal year ends in November. Where is Intellipharmaceutics International based?
Intellipharmaceutics International's address is: 30 Worcester Road, Toronto, ON, Canada, M9W 5X2 What is Intellipharmaceutics International's ISIN number?
Intellipharmaceutics International's international securities identification number is: CA4581733090

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.